ArticleInternational journal of dermatology2026
Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD Nomogram.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SENTINOLD and the Challenge of Meaningful Risk Prediction in Melanoma.International journal of dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel lymph node biopsy (SLNB) is one of the strongest prognostic indicators to date for cutaneous melanoma. However, its indication in elderly patients is controversial due to lower prognostic benefits, comorbidities, and surgical risks.
objectivesThe aim of this study was to develop and validate a predictive model specifically tailored to patients aged ≥ 75 years with cutaneous melanoma, and to compare its performance with the Melanoma Institute Australia (MIA) and Memorial Sloan Kettering Cancer Center (MSKCC) calculators.
methodsA multicenter, retrospective cohort study (SENTINOLD) including 795 patients aged ≥ 75 years was conducted across seven Spanish hospitals, representing one of the largest European datasets of elderly melanoma patients. A multivariable logistic regression model was developed using 12 clinicopathologic variables. Model performance was assessed by discrimination (AUC), calibration, and decision curve analysis (DCA), and compared with MIA and MSKCC calculators. Temporal validation was performed using a hold-out dataset representing the most recent diagnoses.
resultsThe SENTINOLD nomogram demonstrated robust discrimination (AUC = 0.71), outperforming the MSKCC (0.66) and MIA (0.64) models (p < 0.05). Calibration and decision curve analysis confirmed greater clinical usefulness within the 5%-20% decision threshold range. Temporal validation showed stable performance (AUC = 0.68; Brier = 0.187). An interactive web-based calculator is freely available at https://sentinold.netlify.app, allowing clinicians to estimate the risk of SLN positivity using key tumor and patient characteristics.
conclusionsThe SENTINOLD nomogram provides a reliable, user-friendly, and population-specific tool for individualized prediction of sentinel lymph node positivity in elderly melanoma patients. Its use may assist clinicians in guiding SLNB decision-making in this age group, although independent external validation and prospective evaluation of clinical impact are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.